Add-On: Candida Antibodies & Antigen Panel

IgG antibodies to Candida species represent an adaptive immune response following exposure or colonisation. Candida is a commensal yeast present in the gastrointestinal and genitourinary tracts of most healthy individuals; a low-level IgG response is therefore common and does not alone indicate pathology. Elevated IgG may reflect chronic or recurrent mucocutaneous infection, intestinal overgrowth with increased antigen translocation across a compromised epithelial barrier, or systemic candidaemia in the immunocompromised.

Elevated Candida IgG is interpreted in context: in the immunocompetent it may signal recurrent vulvovaginal candidiasis, oral thrush, or suspected intestinal overgrowth; in immunocompromised or hospitalised patients it can support investigation of invasive candidiasis when serological assays are combined with culture and (1,3)-beta-D-glucan or mannan antigen testing. A positive result is not diagnostic on its own and must correlate with clinical presentation.

IgA is the predominant immunoglobulin at mucosal surfaces and the first line of adaptive defence against Candida in the gastrointestinal and respiratory tracts and at genitourinary mucosa. Elevated serum IgA to Candida may indicate active mucosal infection or increased intestinal permeability allowing yeast antigens to reach the lamina propria and stimulate a local and systemic IgA response.

Candida IgA is particularly relevant in suspected mucosal or intestinal overgrowth syndromes. Some functional-medicine practitioners consider elevated IgA more specific for active mucosal disease than IgG, though evidence is limited and the interpretation is contested. In immunocompromised hosts selective IgA deficiency may confound results, and the presence of secretory IgA is the physiological defence rather than serum IgA.

IgM is the first antibody class produced in a primary immune response and reappears during acute re-exposure or reactivation. In Candida serology IgM may rise during acute systemic or mucosal infection, though because Candida exposure is ubiquitous IgM responses are less predictable than in classic acute viral infections.

Elevated Candida IgM can suggest recent or acute infection, though its clinical utility is debated. In invasive candidiasis IgM may appear early, but culture, imaging, and non-antibody biomarkers (beta-glucan, mannan) are the mainstays of diagnosis. In functional testing IgM is sometimes interpreted as a marker of recent antigen exposure or gut translocation, but this application is not validated in mainstream guidelines.

Candida antigen detection targets fungal cell-wall components—most commonly mannan or polysaccharides—circulating in serum. In invasive candidiasis antigens are released from the site of infection and can be detected before antibody responses mature or in immunocompromised patients unable to mount a robust antibody response. Antigen assays are distinct from antibody tests and have a complementary role in rapid diagnosis.

Positive Candida antigen is a more specific marker of active, disseminated, or invasive infection than antibodies alone. It is particularly valuable in neutropenic, transplant, or intensive-care patients where culture may be slow or negative. Dried-blood-spot antigen detection is an emerging method in point-of-care and functional-medicine settings, though its sensitivity and specificity in non-invasive disease are not as well established as hospital-laboratory serum mannan or beta-glucan assays.